Affymax Inc. (Nasdaq: AFFY) warned in its 10-Q filing that it may never achieve profitability and may not be able to continue operations if safety concerns over OMONTYS are not rectified by Takeda Pharmaceutical. Shares of the biopharmaceutical plunged 49 cents to $1.32.
Affymax Warns
May 10, 2013 at 13:23 PM EDT
